Journal: Bioactive Materials

Article Title: LRP-1/CD44-targeted regorafenib nano-delivery system leveraging anti-angiogenesis and synergistic cytotoxicity against peritoneal metastasis of colorectal cancer

doi: 10.1016/j.bioactmat.2025.12.015

Figure Lengend Snippet: Analysis of tumor microenvironment and systemic safety evaluation. (A) Representative immunofluorescence staining of tumor tissues from different treatment groups, showing CD31 + blood vessels (red), CD206 + M2 macrophages (green), and DAPI (blue) for nuclei. Scale bar = 100 μm. (B) Representative H&E-stained histological sections of major organs (heart, liver, spleen, lungs, and kidneys). Scale bar = 200 μm. (C) Quantitative analysis of microvessel density (MVD) based on CD31-positive areas. (D) Quantitative analysis of CD206-positive areas. (E) Statistical summary of the percentage of F4/80 + CD86 + cells within CD45 + cells in tumor tissues, as determined by flow cytometry. (F) Quantitative analysis of the HIF-1α-positive area percentage in tumor tissues from different groups. REG@LF means REG@LFHA NPs, REG@LFHA means REG@LFHA NPs. All statistical data are represented as mean ± SD (n = 3; ∗p < 0.05, ∗∗p < 0.01, ∗∗∗p < 0.001, ∗∗∗∗p < 0.0001).

Article Snippet: Rabbit anti-mouse CD31 polyclonal antibody and rabbit anti-mouse CD206 polyclonal antibody were acquired from Servicebio (Wuhan, China).

Techniques: Immunofluorescence, Staining, Flow Cytometry

Journal: Endocrinology

Article Title: GH Alters Lymphatic Vessels in Female Mice and STAT5 Phosphorylation in Human Lymphatic Endothelial Cells

doi: 10.1210/endocr/bqaf194

Figure Lengend Snippet: LVD quantification using IHC on the hearts of transgenic mice with perturbed GH signaling. (A) Hematoxylin and eosin staining of mouse heart sections from each genotype. (B) Representative images from IHC staining using 2 primary antibodies against LYVE1 and CD31. Fluorescent detection using a red Cy5 or green Alexa488 fluorophore bound to a secondary antibody was used to visualize LYVE1 and CD31, respectively. (C) Fluorescent IHC combined with brightfield imaging using the previously mentioned antibodies toward specific protein targets (LYVE1 and CD31) and using isotype control antibodies. (D, E) The LYVE1-positive area and total area were measured using a pixel classifier in QuPath across 3 to 5 sections per mouse from 3 mice per group (n = 3). The mean LVD ± SEM is shown in each bar graph. Group comparisons were performed using an unpaired t -test, with P -values displayed above the graph. Abbreviations: IHC, immunohistochemistry; LVD, lymphatic vascular density; LYVE1, lymphatic vessel-hyaluronic acid receptor 1.

Article Snippet: The primary antibodies were prepared in TBS-T with 1% BSA at the following concentrations: 4 ug/mL of goat anti-mouse lymphatic vessel-hyaluronic acid receptor 1 (LYVE1; R&D Systems Cat# AF2125, RRID: AB_2297188 ), 3 ug/mL of rabbit anti-mouse CD31 (Proteintech Cat# 28083-1-AP, RRID: AB_2881055 ), or 4 ug/mL goat isotype control antibody (R&D Systems Cat# AB-108-C, RRID: AB_354267 ) or 3 ug/mL rabbit isotype control antibodies (R&D Systems Cat# AB-105-C, RRID: AB_354266 ).

Techniques: Transgenic Assay, Staining, Immunohistochemistry, Imaging, Control